Key result
An amplified sinus P-wave duration of 145-160 ms combined with high systolic pulmonary artery pressure was associated with a higher risk of 1-year arrhythmia recurrence (HR 2.56, p<0.001).
Why the study?
Assessing noninvasive markers of left atrial low-voltage substrate enables the identification of AF patients at risk for arrhythmia recurrence after PVI.
Do amplified sinus P-wave duration and systolic pulmonary artery pressure predict left atrial low-voltage substrate and arrhythmia recurrence in patients with atrial fibrillation undergoing pulmonary vein isolation?
Cohort (n=245)
Yes
Do amplified sinus P-wave duration and systolic pulmonary artery pressure predict left atrial low-voltage substrate and arrhythmia recurrence in patients with atrial fibrillation undergoing pulmonary vein isolation?
Amplified sinus P-wave duration combined with systolic pulmonary artery pressure provides a simple, noninvasive method to predict left atrial remodeling and atrial fibrillation recurrence after pulmonary vein isolation.
BACKGROUND: The assessment of noninvasive markers of left atrial (LA) low-voltage substrate (LVS) enables the identification of atrial fibrillation (AF) patients at risk for arrhythmia recurrence after pulmonary vein isolation (PVI). METHODS: or above. Preprocedural clinical electrocardiogram and echocardiographic data were assessed to identify predictors of LA-LVS. The role of the identified LA-LVS markers in predicting 1-year arrhythmia freedom after PVI was assessed in 245 patients. RESULTS: Significant LA-LVS was identified in 123 (42%) patients. The amplified sinus P-wave duration (APWD) best predicted LA-LVS, with a 148-ms value providing the best-balanced sensitivity (0.81) and specificity (0.88). An APWD over 160 ms was associated with LA-LVS in 96% of patients, whereas an APWD under 145 ms in 15%. Remaining gray zones improved their accuracy by introduction of systolic pulmonary artery pressure (sPAP) of 35 mmHg or above, age, and sex. According to COX regression, the risk of arrhythmia recurrence 12 months following PVI was twofold and threefold higher in patients with APWD 145-160 and over 160 ms, compared to APWD under 145 ms. Integration of pulmonary hypertension further improved the outcome prediction in the intermediate APWD group: Patients with APWD 145-160 ms and normal sPAP had similar outcome than patients with APWD under 145 ms (hazard ratio [HR] 1.62, p = .14), whereas high sPAP implied worse outcome (HR 2.56, p < .001). CONCLUSIONS: The APWD identifies LA-LVS and risk for arrhythmia recurrence after PVI. Our prediction model becomes optimized by means of integration of the pulmonary artery pressure.
No takes yet. Share an insight, caveat, or question.
Weidmann et al. (2021) conducted a cohort in Atrial fibrillation (n=245). Amplified sinus P-wave duration (APWD) and systolic pulmonary artery pressure (sPAP) vs. APWD under 145 ms was evaluated on Arrhythmia recurrence 12 months following PVI (HR 2.56, p=<0.001). An amplified sinus P-wave duration of 145-160 ms combined with high systolic pulmonary artery pressure was associated with a higher risk of 1-year arrhythmia recurrence (HR 2.56, p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: